AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04952441 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RISE Program
Description: Psychoeducational sessions designed to impact Resilience, Insight, Self-Compassion, and Empowerment
Study NCT04952441 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RISE Program
Description: Psychoeducational sessions designed to impact Resilience, Insight, Self-Compassion, and Empowerment
Study NCT01092299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: ER Fast, 90mg, p.o. capsule
Study NCT01092299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: ER Moderate, 90mg, p.o. capsule
Study NCT01092299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: ER Slow, 90mg, p.o. capsule
Study NCT01092299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: MR
Study NCT01092299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1446
Description: IR, 90 mg p.o. capsule
Study NCT03874364 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine gel
Description: 10 ml 2% lidocaine gel is instilled with a syringe through the length of the urethra and kept in site at least 5 minutes prior the introduction of the cystoscope.
Study NCT03874364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Counselling
Description: Patients receive a brochure in the waiting room explaining the procedure in details.
Study NCT03874364 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Counselling
Description: Patients receive a brochure in the waiting room explaining the procedure in details.
Study NCT03874364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monitor
Description: Patients are allowed to view and follow the procedure on a monitor connected to the cystoscope's camera.
Study NCT03874364 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Monitor
Description: Patients are allowed to view and follow the procedure on a monitor connected to the cystoscope's camera.
Study NCT03874364 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Lubricating gel
Description: 10 ml plain lubrificant gel is instilled with a syringe through the length of the urethra and kept in site at least 5 minutes prior the introduction of the cystoscope.
Study NCT03874364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No counselling
Description: Patients won't receive a brochure in the waiting room explaining the procedure in details.
Study NCT03874364 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No counselling
Description: Patients won't receive a brochure in the waiting room explaining the procedure in details.
Study NCT03874364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No monitor
Description: Patients are not allowed to view and follow the procedure on a monitor connected to the cystoscope's camera.
Study NCT03874364 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No monitor
Description: Patients are not allowed to view and follow the procedure on a monitor connected to the cystoscope's camera.
Study NCT03434119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glargine/Lixisenatide
Description: Insulin glargine (100 units per milliliter \[U/mL\]) and lixisenatide (33 micrograms per milliliter \[mcg/mL\]) self administered by a subcutaneous injection using a prefilled pen. Dose was individually titrated to achieve target fasting self-monitoring of plasma glucose (SMPG) of 80 to 100 milligrams per deciliter (mg/dL) (4.4 to 5.6 millimoles per liter \[mmol/L\]) while avoiding hypoglycemia.
Study NCT03434119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine (HOE901)
Description: Insulin glargine 100 U/mL self-administered by a subcutaneous injection using a prefilled pen. Dose was individually titrated to achieve target fasting SMPG of 80 to 100 mg/dL (4.4 to 5.6 mmol/L) while avoiding hypoglycemia.
Study NCT03434119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Background therapy
Description: Oral Anti diabetics Drugs (OADs) administered orally according to the locally approved label.
Study NCT03434119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Background therapy
Description: Oral Anti diabetics Drugs (OADs) administered orally according to the locally approved label.
Study NCT02777593 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: GORE® TAG® Thoracic Branch Endoprosthesis
Description: Endovascular repair with the TBE Device
Study NCT03704818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5mg
Description: Dapagliflozin treatment taken daily for 4-weeks.
Study NCT03704818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: Placebo treatment taken daily for 4-weeks.
Study NCT02523534 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI images will be taken in conjunction with the clinically indicated cardiac MRI.
Study NCT02523534 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECG
Description: ECG readings will be taken prior to the participants clinically indicated procedure.
Study NCT02813226 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Molecular Imaging
Description: Baseline and follow-up FDG PET-CT and DCFPyL PET-CT
Study NCT02873611 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: patients will undergo an additional MRI testing of apprx. 0.5-1 hour.
Study NCT00234975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir/Ritonavir
Description: 400 mg/ 100 mg BID. Both arms use Kaletra 400/100 mg BID, plus NRTI chosen by the investigator
Study NCT04025099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internal Cues
Description: The intuitive eating curriculum that was pilot tested and adapted has been modified for use for the Internal Cues group with college-aged females for delivery over a 10-week time period.~The classes will be delivered by two Registered Dietitians and Certified Intuitive Eating Counselors from the University of Delaware, Julia Katcher and Maryann Eastep.~During the Internal Cues group's intuitive eating classes, participants will, as a group, eat dinner that is prepared by ServSafe certified undergraduate dietetics students in the test kitchen in the STAR Tower. This dinner will allow the participants to experientially learn the intuitive eating principles taught in class.~The yoga classes will be adapted to all levels of experience, mobility, and body size. Specific breathing techniques and body positive language will be incorporated into a body-positive yoga training done by Ms. Lisa Jones, RYT.
Study NCT02873611 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: genicular ablation procedure
Study NCT01168817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY60-4552 plus Vardenafil
Description: Treatment with 3 tablets once daily for 4 weeks (Vardenafil 10 mg plus BAY60-4552 1.0 mg)
Study NCT01168817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vardenafil
Description: Treatment with 3 tablets once daily for 4 weeks (Vardenafil 20 mg)
Study NCT01168817 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with 3 tablets once daily for 4 weeks (Placebo)
Study NCT01056224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
Study NCT01387568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Infusion
Description: children in group L received i.v. lidocaine 1.5 mg/kg followed by infusion at 1.5 mg. kg-1.h-1. and were continued up to 6 hours postoperatively
Study NCT01387568 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline Infusion
Description: children in group P received i.v. saline 0.9% 1 ml/kg followed by infusion at 0.1 ml. kg-1.h-1,and were continued up to 6 hours postoperatively
Study NCT02528214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
Study NCT02528214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection, Subcutaneous injection in the abdomen, upper thigh or upper arm.
Study NCT02528214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral corticosteroid therapy (prednisone/prednisolone)
Description: Oral administration.
Study NCT02528214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral corticosteroid therapy (prednisone/prednisolone)
Description: Oral administration.
Study NCT02528214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroid (ICS) therapy
Description: Oral inhalation, stable dose (high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy).
Study NCT02528214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled corticosteroid (ICS) therapy
Description: Oral inhalation, stable dose (high dose) of ICS in combination with up to 2 other controller medicines (second or third controller therapy).
Study NCT02528214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol/Salbutamol
Description: Oral inhalation as needed.
Study NCT02528214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Albuterol/Salbutamol
Description: Oral inhalation as needed.
Study NCT01092299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IR
Study NCT02528214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levalbuterol/Levosalbutamol
Description: Oral inhalation as needed.
Study NCT04025099 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: External Cues
Description: The 10-week traditional healthy weight program for the External Cues group was created by a Graduate Assistant based on MyPlate principles.~The External Cues classes will be delivered by two Registered Dietitians from the University of Delaware, Julia Katcher and Maryann Eastep.~During the External Cues group's healthy eating classes, participants will, as a group, eat dinner that is prepared by ServSafe certified undergraduate dietetics students in the test kitchen in the STAR Tower. This dinner will allow the participants to experientially learn how to properly portion their meals to meet their caloric needs, in line with traditional education about weight control.~Students randomized to the External Cues group will receive a UD fitness pass and will be able to choose from select cardio-based fitness classes in order to meet public health recommendations for physical activity.
Study NCT04598061 — intervention group
Intervention type: DRUG
Intervention: Dexmedetomidine IV
Description: Dexmedetomidine IV
Study NCT02528214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levalbuterol/Levosalbutamol
Description: Oral inhalation as needed.
Study NCT01234506 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: secoisolariciresinol diglucoside
Description: SDG supplementation as a packet of 0.8g/day of BeneFlax containing 300 mg SDG for 24 weeks
Study NCT01234506 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: secoisolariciresinol diglucoside
Description: SDG supplementation as a packet of 0.8g/day of BeneFlax containing 300 mg SDG for 24 weeks
Study NCT06380231 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kangaroo mother care (KMC)
Description: Kangaroo mother care is a simple care that aims to protect the health and well-being of premature babies, where skin-to-skin contact is achieved by placing the premature baby in an upright position, face down, between the parent's breasts, wearing only a diaper and a cap.~Before the experimental group infant was given to the mother, his/her hat was put on, and clothes were removed. The infant was placed in an upright position (approximately 60°) between the mother's two breasts. To enable the infant to breathe, his/her head was positioned to the right or left with ear touching the mother's chest, arms and legs were flexed, and hip was abducted. The mother supported the infant's neck and back with one hand and the hips with the other. The infant's back was covered with a cotton blanket. An noninvasive pulse Co-oximetry was attached to the right wrist of the infant to evaluate heart rate, oxygen saturation, and perfusion index.
Study NCT03249623 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Beacon Caresystem
Description: The core of the system is a set of physiological models including pulmonary gas exchange, acid-base chemistry, lung mechanics, and respiratory drive. The Beacon Caresystem tunes these models to the individual patient such that they describe accurately current measurements. Once tuned, the models are used by the system to simulate the effects of changing ventilator settings. The results of these simulations are then used calculate the clinical benefit of changing ventilator settings by balancing the competing goals of mechanical ventilation.
Study NCT00749151 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: telephone counseling
Description: First time callers to telephone help line agreed to one year follow-up on smoking cessation.
Study NCT01764984 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee arthroplasty
Description: Total knee arthroplasty using parapatellar approach and postero-stabilized implants.
Study NCT01764984 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Total knee arthroplasty
Description: Total knee arthroplasty using parapatellar approach and postero-stabilized implants.
Study NCT03220191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: palbociclib tablet formulation
Study NCT03220191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: rabeprazole as PPI
Study NCT04216108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitrectomy (23G gauge needle)
Description: Vitrectomy surgery with 23G gauge needle technique
Study NCT04216108 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitrectomy (27G gauge needle)
Description: Vitrectomy surgery with 27G gauge needle technique
Study NCT01753193 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Description: Intravenous infusion of anifrolumab will be administered as 1000 mg Q4W from Day 1 (Week 0) until 12-Feb-2015 (approval of protocol amendment 4); and thereafter 300 mg Q4W up to 3 years or until the sponsor discontinued development of anifrolumab, whichever came first.
Study NCT04612361 — intervention group
Intervention type: OTHER
Intervention: insommnia severity index questionnaire
Description: insomnia severity index questionnaire and scoring system
Study NCT03273439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive TMS
Description: Prior to each TMS administration, motor threshold was determined by stimulating the left motor strip with the lowest possible energy to produce, within 10 stimuli, at least 5 evoked potentials Z0.05 . In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of motor threshold (MT) for 5-s intervals with 30-s intertrain interval. 30 trains were administered each day (MondayFriday) for 4 consecutive weeks (total stimuli=30,000).
Study NCT03273439 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham rTMS, without stimulation
Study NCT02431039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEOSORB PLUS
Description: Fascia and subcutaneous tissue repaired by antibacterial suture materials (Chlorhexidine diacetate coated PGLA910)
Study NCT02431039 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NEOSORB
Description: Fascia and subcutaneous tissue repaired by non-antibacterial suture materials (PGLA910)
Study NCT01092299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ER/MR
Study NCT01472809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZYGK1
Description: ZYGK1 Tablets: 0.125, 0.25, 0.5, 1, 2, .... mg.~Dose escalation will continue till single AE occurs in any block of 3 volunteers on ZYGK1 or pharmacokinetic (dose linearity) saturation is reached or desired PK/PD effect is achieved
Study NCT01472809 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Tablets: 0.125, 0.25, 0.5, 1, 2, ... mg
Study NCT00959387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction TP chemotherapy
Description: 3 cycles of paclitaxel 175mg/m2 and cisplatin 80mg/m2 q3w. All patients received supportive care during radiotherapy, including dietary measures, local antiseptics and laser therapy as preventive and curative support for oral mucositis.
Study NCT00959387 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (CRT)
Description: Patients were treated with 2-dimensional radiation therapy planning (6MV photon beams). A combination of lateral-opposed portals, anterior and lateral wedged fields was used to treat the primary tumor and the lymph nodes. The primary tumor, macroscopically affected lymph nodes and bilateral cervical plus supraclavicular lymph chains were treated with five fractions of 2Gy per week for 5 weeks (up to a total of 50Gy). Gross tumor volume was defined as the primary gross tumor or involved node, and this measure was based on clinical, radiological and endoscopic examinations. An additional margin of 1.0cm was added to the GTV to create the CTV. A boost of five fractions of 2Gy per week for 2 additional weeks (up to a total dose of 70Gy) was prescribed to the CTV plus a margin of 1.0cm.
Study NCT00781131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: pregabalin 75 or 150 mg
Study NCT00781131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: lactulose placebo
Study NCT02252484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight Loss Program
Description: Program has four main components: diet, physical activity, coaching and diet and exercise monitoring. The program is tailored to each individual in the study.
Study NCT02252484 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care for this patient population.
Study NCT00117585 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment Phase 1
Description: * Patient Education~* Physical Therapy Exercises~* Increased Salt Intake~* Elevation of head of bed with 2-4 inch wedge~* Medication Review by MD, Pharma
Study NCT00117585 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Treatment Phase 2
Description: Subjects receive Treatment Phase 2 if they are still orthostatic after receiving Treatment Phase 1.~* Fludrocortisone~* Salt tablet
Study NCT00117585 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment Phase 3
Description: Subjects still experiencing orthostatic hypotension after receiving Treatment Phases 1 and 2 move on to Treatment Phase 3. Individualized treatment is based on subspecialty or orthostatic hypotension consultation at the medical center. Subjects are followed for the duration of their hospital stay, on average 4 weeks.
Study NCT02981602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS-HBVRx
Description: Ascending multiple doses of IONIS-HBVRx by subcutaneous (SC) injection
Study NCT02981602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03049137 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer Guided Stent Augmentation
Description: Defective alveolar ridge is to be replaced by simultaneous implant placement with ring graft augmentation (Trephine Drill to obtain the ring graft autogenous bone) using computer guided stent and covered with Platelet-rich fibrin (PRF), by using venous blood from the patient, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 Revolution Per Minute (RPM) for 10 minutes.
Study NCT03049137 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free Hand Augmentation
Description: Defective alveolar ridge is to be replaced by Free Hand simultaneous implant placement with ring graft augmentation (Trephine Drill to obtain the ring graft autogenous bone) and covered with Platelet-rich fibrin (PRF), by using venous blood from the patient, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM for 10 minutes.
Study NCT03049137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Study NCT03049137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-rich fibrin (PRF)
Study NCT03049137 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: implant
Study NCT04212325 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group C (Continuous sciatic nerve block)
Description: Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the popliteal location 1-3 cm cephalad to the sciatic bifurcation. After Catheter placement outcome measures will be assessed.
Study NCT04212325 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group S (sciatic nerve block)
Description: Patients randomized to this group will receive a sciatic nerve block at the popliteal location 1-3 cm cephalad to the sciatic bifurcation. After single injection sciatic nerve block, outcome measures will be assessed.
Study NCT02291510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Met DR
Description: metformin delayed-release tablets